Maslowski A H
Middlemore Hospital, Auckland, New Zealand.
Am Heart J. 1991 Jan;121(1 Pt 2):323-8. doi: 10.1016/0002-8703(91)90866-g.
This study investigated the safety and efficacy of doxazosin treatment in a large population of patients (n = 336) with essential hypertension and assessed the effect of doxazosin on the serum lipid profile and the calculated risk of developing coronary heart disease. Patients were assigned to two groups: those with a baseline diastolic blood pressure greater than or equal to 95 mm Hg (group 1) and those with a baseline diastolic blood pressure less than 95 mm Hg (group 2) that was controlled by previous antihypertensive therapy. Doxazosin treatment (monotherapy in 76.2% of patients) significantly (p less than 0.05) reduced the blood pressure of patients in group 1 (-23/-17 mm Hg) after 10 weeks and maintained the control of blood pressure for patients in group 2. Heart rate was essentially unchanged in both groups. Mean final daily doses of 3.6 and 3.2 mg were achieved in groups 1 and 2, respectively. Treatment with doxazosin improved the severity category of hypertension for 88.4% of patients in group 1; 87.3% of patients were considered a therapy success. Doxazosin had a favorable effect on the serum lipid profile in both groups of patients. The majority of lipid changes achieved statistical significance and resulted in a significant 27% decrease in the calculated risk of developing coronary heart disease. Doxazosin was well tolerated; only 24.1% of patients had side effects that were related or possibly related to treatment. In nine (2.7%) patients the dose of doxazosin was reduced and 26 (7.7%) patients withdrew from doxazosin therapy because of side effects.
本研究调查了多沙唑嗪治疗大量原发性高血压患者（n = 336）的安全性和有效性，并评估了多沙唑嗪对血清脂质谱以及冠心病发病计算风险的影响。患者被分为两组：基线舒张压大于或等于95 mmHg的患者（第1组）和基线舒张压小于95 mmHg且之前通过抗高血压治疗得到控制的患者（第2组）。多沙唑嗪治疗（76.2%的患者为单一疗法）在10周后显著（p < 0.05）降低了第1组患者的血压（-23 / -17 mmHg），并维持了第2组患者的血压控制。两组患者的心率基本未变。第1组和第2组最终的平均每日剂量分别达到3.6 mg和3.2 mg。多沙唑嗪治疗使第1组88.4%的患者高血压严重程度类别得到改善；87.3%的患者被认为治疗成功。多沙唑嗪对两组患者的血清脂质谱均有有利影响。大多数脂质变化具有统计学意义，使冠心病发病计算风险显著降低了27%。多沙唑嗪耐受性良好；仅24.1%的患者出现与治疗相关或可能相关的副作用。9名（2.7%）患者减少了多沙唑嗪剂量，26名（7.7%）患者因副作用退出多沙唑嗪治疗。
